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Galectin-3, a member of a large family of animal based β-galactoside-binding lectins has been shown
to play a role in a number of cellular and pathogenic processes. This protein has been shown throughout
the literature to interact with a diverse multiplicity of proteins, involved in a diverse array of cellular
functions, including cell migration and cell proliferation, both of which are of particular in regards to cancer
research. Covalent modifications to Galectin-3 that can undermine its binding partner interactions would
definitely prove useful in such an enterprise.
DX-52-1, a semisynthetic an analog of the natural product quinocarcin, has been shown by the Fenteany
Group, to demonstrate remarkable anti-migration and anti-proliferation properties with regard to a number
of cancer cell lines. Furthermore this molecule has been shown to bind strongly and specifically to Galectin3 and Radixin. In the course of this research DX-52-1 has been shown to modestly undermine a number of
binding partner interactions of Galectin-3. It has also been demonstrated that the phosphorylation of
Galectin-3 also influences its binding to DX-52-1. It has been further demonstrated that DX-52-1 may have
an even more potent effect on the formation of higher order complexes that contain Galectin-3. This
observation may serve to further explain the strong anti-migration and anti-proliferation effects of DX-521.
In the course of this work, efforts to map the binding site of DX-52-1 on Galectin-3 were undertaken.
In the course of those efforts a novel method to narrow down potential binding sites was developed.
Furthermore structure activity relationship studies were performed to determine the importance of certain
functional groups on the binding properties of DX-52-1 in regard to Galectin-3 and Radixin as wells as its
anti-cellular properties. The results of these SAR studies show a link between the binding of DX-52-1 to
Galectin-3 and its anti-migration and anti-proliferation properties.
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Introduction
The process through which a cell translocates itself from on position to another, is known
as cell migration, an essential component to a number of biological processes both normal and
pathogenic. Such processes include but are not limited to embryonic development, immunity,
wound healing, angiogenesis, inflammation, tumor invasion, and metathesis (1, 2). In the case of
immunity leukocytes must migrate into tissues in order to contend with infecting bacteria (3).
Wound healing involves cells that surround the site of a wound and then migrate inward for the
purpose of closing that wound (4).
Cell migration is arguably just as important to the progression of a cancer as is the ability
of malignant cells to propagate uncontrollably. Cancerous cells that constitute a tumor like normal
cells require blood vessels in order to continue propagating. Without blood vessels the size to
which a tumor can grow is strictly limited (5). The process by which cells migrate from already
existing blood vessels to a tumor in order to form new blood vessels is known as angiogenesis (5).
It is through this process tumors are permitted to continue to grow and flourish. Cell migration is
also critically important to the process of metathesis. This process involves cells breaking away
from the primary tumor and migrating to nearby blood and/or lymphatic vessels in order to gain
access to the circulatory system (6, 7). It is at this point the cancerous cells can easily make their
way to other parts of the body and form any number of secondary tumors (5-7). Clearly
angiogenesis and metathesis are critically important to the progression of cancers. Due to the fact
that cell migration is an integral part of the aforementioned processes, it stands to reason the ability
to inhibit the process of cell migration would useful in the development of therapeutic strategies.
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The dynamics of the filamentous protein complexes that serve as a major component of the
cytoskeleton, serve as the primary driving force of cell migration in multi-cellular organisms (2,
8). Actin is a 42 kD globular protein that exists in two primary states, the monomer G-Actin
(globular) and the polymer F- Actin (filamentous) (2). The frequent interchange between these two
states are responsible for a number of cellular processes including cell migration, cell signaling,
organelle movement, cell division and muscle contraction (9). The process by which F-Actin is
formed from G-Actinin (Figure 0-1) begins with the binding of ATP to G-Actin. These activated
G-Actin can form oligomers, which have the potential to form nuclei, which initiate a rapid
polymerization of other ATP bound G-Actin into F-Actin (9, 10). There are two distinct ends to
the Actin filament, the barbed end and the pointed end. The Actin filament grows as it adds
additional subunits to its barbed end, pushing against the cell membrane, and thus acts as the
driving force of cell migration (8-10). The Actin subunits at the pointed end of the filament
hydrolyze their bound ATP and as a result break away to be recycled allowing the cell migration
process to be maintained (Figure 0-2). This overall process known as “treadmilling” can be
inhibited either by molecules that interact with the Actin itself or by interacting with proteins that
interact with the Actinin filaments directly or indirectly (2). Either approach has the potential of
inhibiting cell migration which is important to the progression of cancers. This dissertation is
concerned with the latter approach.
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Figure 0-1: Actin Polymerization (http://en.wikipedia.org/wiki/Actin)

Figure 0-2: Animal cell migration propelled by the “treadmilling” of F-Actin (2)
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There are a wide multitude of compounds that have been shown to inhibit cell migration
(2). One such compound DX-52-1 (Figure 1-1) has been studied extensively by the Fenteany
Group. DX-52-1 has demonstrated remarkable anti-proliferation and anti-migratory properties
against a number of cancer lines (2, 11, 12). Though a series of pull down assays involving DX52-1, the Fenteany Group was able isolate two proteins that strongly interact with DX-52-1. These
proteins are Radixin and Galectin-3 (11, 12). This dissertation will focus on the relationship
between Galectin-3 and DX-52-1. The reason for the selection of Galectin-3 as a focus of this work
is that Galectin-3 has been demonstrated in the literature to interact with both β-Catenin (interacts
with cell adhesion protein Cadherin) and α-Actinin (interacts with F-Actin), both of which play
parts in cell migration (2, 12). Furthermore Galectin-3 has be reported extensively in the literature
to interaction a wide multitude of proteins that affect a wide multitude of cellular processes (1214). Elevated levels of Galectin-3 has also been linked to a number of different cancers (12-14).
This dissertation, the main body of which is divided into four chapters, will discuss
research and observations concerning the interaction of DX-52-1 with Galectin-3 and the ability
of DX-52-1 to influence the interaction between Galectin-3 and its protein binding partners. This
dissertation will also describe effort to streamline the search for DX-52-1 binding site of Galectin3. Furthermore this work will also discuss investigations involving the importance of certain
functional groups of DX-52-1 in regard to its binding properties as well as its anti-cellular
properties.
The first chapter will address two topics. The first topic involves the determination of the
effect of the phosphorylation of Galectin-3 on the ability of the protein to bind DX-52-1. The
second topic will involve the investigation the effects of Galectin-3 phosphorylation and the
binding of DX-52-1 upon the ability of Galectin-3 to bind to each of ten protein binding partners.
4

These ten protein are involved in a diverse array of cellular processes. The effects of
phosphorylation and the binding of DX-52-1 were both tested separately and together. The
possible biological implications of the results described in the first chapter will also be discussed.
The second chapter will discuss two topics. One such topic will involve the observation of
the effect of binding β-Catenin to Galectin-3 on its ability to subsequently bind DX-52-1. The
effect α-Actinin binding to Galectin-3 upon its ability to bind DX-52-1 will also be examined. It
stands to reason that the ability of DX-52-1 to affect cellular processes by binding to Galectin-3
maybe affected by the proteins Galectin-3 might already be interacting with. The other topic of the
chapter concerns the formation of a three protein complex consisting of β-Catenin, Galectin-3, and
α-Actinin. This complex is hypothesized to have Galectin-3 connecting β-Catenin to α-Actinin.
This chapter will discuss experimental results supporting this hypothesis. The effect of DX-52-1
on the formation of this three protein complex will also be described and compared its effects on
the binding properties of Galectin-3 discussed in the first chapter. The possible biological
implications will also be addressed.
The third chapter will discuss the problem of direct determination of the DX-52-1 binding
site via mass spectrometry. Experimental results that illuminate the cause of this problem will be
discussed. Normally the alternative method would be the employment of alanine scanning via site
directed mutagenesis. However a novel experimental method has streamlined what would
normally be a much lengthier process. The novel method localizes the DX-52-1 binding site to a
single tryptic fragment of Galectin-3 thus reducing the number of candidate amino acids that need
to be subjected to alanine scanning. The development and experimental results of the novel method
will be discussed.
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The fourth chapter will discuss three topics. The first topic will involve the investigation
of the effect of the modification of certain functional groups of DX-52-1 on its ability to bind to
Galectin-3 as well as Radixin. The second topic of the chapter will involve measuring the effect
of functional group modification on the ability of DX-52-1 to inhibit the migration of mammalian
cells. The third topic will involve the observation of the effect of the modification of the functional
groups of DX-52-1 upon its to inhibit cell proliferation.
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Chapter 1
Interactions of Galectin-3 with its Binding Partners
Introduction
Galectin-3 is a 31-kDa protein that is a member of a large family of β-galactoside-binding
lectins in animal cells (1-3). Galectin-3 has been classified as having several distinct structural
domains: an N-terminal domain consisting of a 12 amino-acid segment that contains two casein
kinase I phosphorylation sites, a repeated collagen-like sequence rich in proline, glycine, tyrosine
and glutamine residues and a globular C-terminal half with a carbohydrate recognition domain
(CRD) (1, 4). Galectin-3 plays a role in a broad range of cellular processes (2, 5) including premRNA splicing, cell differentiation, cell adhesion to extracellular matrices, cell-cell adhesion, cell
proliferation and cell motility (6, 7). Furthermore, Galectin-3 is involved in the regulation of
apoptosis, oncogenesis and cancer cell metastasis (3, 10, 12). Galectin-3 interacts with a broad
range of proteins of varied function (6, 7). Galectin-3 is found in the cytoplasm, nucleus,
mitochondria, and associated to the cell membrane and extracellular spaces (6, 7). Functional
dissection of Galectin-3’s many interactions that are independent of carbohydrate binding
interactions with other proteins or RNA is a pressing need in the field.
We have previously discovered that DX-52-1 (Figure 1-1), a semisynthetic analog of the
tetrahydroisoquinoline natural product quinocarcin (also known as quinocarmycin), is an inhibitor
of animal cell migration (7). DX-52-1 binds and inhibits functions of Galectin-3, as well as the
membrane-cytoskeleton linker protein Radixin, through alkylation of specific amino acid residues
on the proteins (7, 8). We then discovered that another tetrahydroisoquinoline, HUK-921, also
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inhibits cell migration and has greater selectivity than DX-52-1 for Galectin-3 over radixin (8).
DX-52-1 and HUK-921 bind to the CRD of Galectin-3 but are not competitive with the binding of
β-galactosides, implying that these tetrahydroisoquinolines interfere with the interaction of
Galectin-3 with proteins or other non-carbohydrate molecules (8). DX-52-1 and HUK-921 most
likely act to inhibit the Galectin-3’s ability to bind to its binding partners, either by direct steric
hindrance or by an allosteric mechanism. DX-52-1 and related tetrahydroisoquinolines therefore
represent potentially very important tools for understanding the functions of Galectin-3,
particularly interactions with other proteins that may play a role in cell migration.

DX-52-1

BDX
Figure 1-1: Structures of DX-52-1 and Biotinylated DX-52-1 (BDX). BDX was prepared by
EDC/NHS mediated coupling between DX-52-1 and biotin-PEG3-amine, as previously described
(Kahsai et al., 2006).
Galectin-3 has been shown to be phosphorylated on serine 6 and serine 12, and reversible
phosphorylation appears to be an “on/off” switch regulating interactions between Galectin-3 and
9

a number of its binding partners (9-11). Casein kinase I phosphorylates Ser 6 (major) and Ser 12
(minor) (9). Because of the interaction of Galectin-3 with a multiplicity of proteins affecting a
large number of cellular functions, the phosphorylation of Galectin-3 at Ser 6 and Ser 12 could
have substantial effects on overall cell function and viability. For this reason, we chose to
investigate the effect of Ser 6/Ser 12 phosphorylation of Galectin-3 upon several of its binding
partners. These binding partners include Akt, Axin, Bcl-2, β-Catenin, CD40, Gemin-4, K-Ras,
OCA-B, Sufu and TCF4 (1, 12-19). Akt is a serine/threonine kinase that is activated by Galectin3 and participates with Galectin-3 in the control of apoptosis (19, 20). Axin is a negative regulator
in the Wnt signaling pathway and plays a role in proteasome degradation (13, 21). Bcl-2 plays a
role in the regulation of cellular apoptosis and has been found to have significant sequence
similarity with Galectin-3 (22, 23). β-Catenin is part of the cadherin-containing adherens junction
complex and plays a role in the Wnt signaling pathway (16, 24). CD40 plays a role in antigen
presentation (17, 25). Gemin-4 plays a role in the splicing of pre-mRNA (14, 26). K-Ras has an
effect upon both cell motility and expression of MMP-2 (12, 27-29) Sufu is a signaling protein
that serves as a negative regulator of the Hedgehog signal transduction pathway (30, 31). OCA-B
is a transcriptional co-activator involved in immune responses (15, 32). TCF4 functions as an
immunoglobulin transcription factor (15, 34). We also looked at the combined effects of Ser 6/Ser
12 phosphorylation and DX-52-1 binding upon the interaction of Galectin-3 with its binding
partners. Furthermore, we investigated the effect of the phosphorylation at Ser 6 and Ser 12 on the
binding of DX-52-1 to Galectin-3.
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Materials and Methods
Expression and Purification of Galectin-3
Human Galectin-3 was expressed as a GST fusion protein in the pGEX-2T-1 vector
transformed into BL21 (DE3) E. coli cells. Small amounts of glycerol stock were removed by
sterile 200 µl pipette tips to seed cultures in 40 ml of Luria-Bertani medium containing 1 mM
ampicillin (LB-Amp). After growing the cells overnight at 37 °C, the culture was transferred to a
flask containing 4LLB-Amp, followed by incubation at 37 °C until the absorbance at 600 nm was
between 0.6 and 0.9. Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to a final
concentration of 1 mM, and the culture was incubated further at 37 °C for 5 h. The cells were then
harvested by centrifugation (4,500 g for 10 min). The cell pellets were re-suspended in 140 ml of
a lysis buffer consisting of 50 mM Tris (pH 7.5), 1 mg/ml lysozyme, 1 g/ml leupeptin, 1 g/ml
pepstatin A, 0.1 mM phenylmethylsulfonyl fluoride, 0.1 mM benzamidine and 1% Triton X-100
at 4 °C. The resuspended cells were homogenized and then incubated on ice for 30 min. The
homogenate was centrifuged at 14,500 g for thirty min. A glutathione-agarose bead slurry (2 ml)
was added to the lysate. The samples were rotated overnight at 4 °C. The beads were centrifuged
at 4,500 g for 5 min and the lysate was discarded. The beads were re-suspended in 40 ml 50 mM
Tris (pH 7.5) at 4,500 g for 5 min three times, with removal of supernatant and resuspension of
beads between each spin. The beads were then resuspended in 8 ml of 50 mM Tris (pH 7.5)
containing 10 units/ml thrombin. The sample was rotated overnight at 4°C. The samples were
centrifuged at 4,500 g for 5 min, and the supernatant was transferred to a new tube. Protein
concentration was determined by absorbance measurement at 280 nm (extinction coefficient of
33,710 M-1 cm-1 was estimated using “Richard’s Protein Calculator” website). The supernatant
was concentrated with a YM-10 Centricon filter until the final protein concentration reached 50
11

M. The concentrated protein was then aliquoted and flash frozen by immersion in liquid nitrogen
prior to storage at -80 oC.
Galectin-3 Binding Partner Plasmids
Plasmids expressing Galectin-3 binding partners as glutathione S-transferase (GST) fusion
proteins were transformed into BL21 (DE3) Escherichia coli cells, with expression of the Galectin3 binding partners as described above for Galectin-3. The cells were stored as glycerol stocks at 80 oC. Axin, Bcl-2, CD40, Gemin-4, OCA-B, Sufu and TCF4 were expressed from pGEX-2T-1
plasmids provided by W. Has (Columbia University), J. Teodoro (McGill University), F. Weiland
(Heidelberg University), E. Briggs (Howard Hughes Medical Institute), R. G. Roeder (Rockefeller
University), H. Miki (Osaka University) and Z. Yi (Ludwig Institute for Cancer Research),
respectively. β-Catenin was expressed from a pGEX-4T-1 plasmid provided by Z.J. Sun (Stanford
University). Akt was expressed from a pGEX-4T-2 plasmid provided by M. Rane (University of
Louisville). K-Ras was expressed from a pGEX-5X-1 plasmid provided by M. Sammer
(Bioinformatics Institute, A*STAR, Singapore).
Casein Kinase I-Catalyzed Phosphorylation of Galectin-3
Casein kinase I (CK1) was purchased from New England Biolabs. Reaction mixtures
consisted of 20 M Galectin-3, 300 M ATP, 1X CK1 reaction buffer and 1,000 units of CK1.
Control mixtures were identical to the reaction mixtures with the exception of the CK1 being
omitted. Reaction and control mixtures were both incubated at 30 oC for 20 h.
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Biotinylated DX-52-1 Binding Assays
Biotinylated DX-52-1 (BDX) was synthesized as previously described (8). On the first day
CK1 and control reaction mixtures were prepared and incubated. On the second day BDX was
added to both mixtures to a concentration of 900 M. The mixtures were then incubated at 4 oC
for 27 h. On the third day equal volumes of sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) loading buffer were added to each mixture. After boiling for 15 min,
the mixtures were separated on a 12% polyacrylamide gel at 70 mA for 35 min before being
transferred to polyvinylidene difluoride (PVDF) membrane at 200 mA for 1 h. The membrane was
blocked with a solution of 5% milk in Tris-buffered saline-0.05% Tween 20 (TBS-T) at pH 7.6 for
1 h. Horseradish peroxidase (HRP)-linked anti-biotin antibody (Cell Signaling) was diluted 1,000fold in milk/TBS-T and applied to the membrane for 1 h. The membrane was given three 15 min
washes in TBS-T. Pierce Enhanced Chemiluminescence (ECL) Western Blotting Reagent was
applied to the membrane for 5 min. The bands were visualized and their intensities quantified with
Bio-Rad Quantity One software.
Galetin-3/Binding Partner Pull down Assays
Each Galectin-3 binding partner was expressed as a GST fusion protein in BL21 (DE3) E.
coli cells. On the first day CK1 and control reaction mixtures were prepared and incubated for 20
h. Small amounts of glycerol stock were removed by sterile 200 µl pipette tips to seed 10 mL LBAmp cultures. The cells are grown overnight at 37 °C. On the second day, each control mixture
was divided into half. To the first half (designated “Cont”), DMSO was added to a concentration
of 1% by volume. To the second half (designated “DX”), DX-52-1 was added (as a solution in
DMSO) to a concentration of 900 M. The CK1 reaction mixture was also divided in half. To the
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first half of the reaction mixture (designated “Phos”), DMSO was added to a concentration of 1%.
To the second half of the reaction mixture (designated “DX-52-1/Phos”), DX-52-1 was added to a
concentration of 900 M. Cont, DX, Phos and DX-52-1/Phos were each incubated at 4 oC for 20
h.
On the third day, the beads were centrifuged at 4,500 g for 5 min, and the lysate was
discarded. The beads for each binding partner were resuspended in 15 ml 50 mM Tris (pH 7.5),
centrifuged at 4,500 g for 5 min and the supernatant was discarded. The aforementioned step was
repeated twice. Each set of beads was resuspended in 1 ml 50 mM Tris (pH 7.5), (in the case of
K-Ras, 10 mM GTP was included). For each assay an equal volume of glutathione beads bearing
a GST-binding partner fusion protein was added to the Cont, DX, Phos and DX/Phos samples. The
mixtures are rotated for 20 h at 4 oC.
On the fourth day, the mixtures were centrifuged, and the supernatants discarded. The
beads were washed three times with 50 mM Tris (pH 7.5), with final volumes kept minimal. 40 l
SDS-PAGE loading buffer was added to each set of beads. After boiling for 15 min, the mixtures
were then separated on a 12% polyacrylamide gel before being transferred to a PVDF membrane.
The membrane was blocked with a 5% milk/TBS-T solution for 1 h. Mouse antiGalectin-3 (Santa
Cruz Biotechnology) was diluted 1,000 fold in 5% milk/TBS-T and applied to the membrane for
1 h. The membrane was washed three times with TBS-T for 15 min per wash. Goat anti-mouseHRP was diluted 10,000-fold in 5% milk/TBS-T and applied to the membrane for 1 h. The
membrane was given three 15 min washes in TBS-T. Pierce ECL Western Blotting Reagent was
then applied to the membrane for 5 min. The bands were visualized and their intensities quantified
with Bio-Rad Quantity One software.
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Results and Discussion
The structures of DX-52-1 and BDX are shown in Figure 1-1. The BDX binding assay
shows that Ser 6/Ser 12 phosphorylation of Galectin-3 has a very substantial effect on the binding
of DX-52-1 upon the protein (Figure 1-2). Galectin-3 phosphorylated in such a manner shows
increased binding of DX-52-1 by 320% ± 102% (mean ± SEM), as derived from the data displayed
in Figure 1-2. There appear to be two possible explanations for this dramatic increase in DX-52-1
binding. The first possibility is that Ser 6/Ser 12 phosphorylation of Galectin-3 by CK1 increases
the on rate or decreases the off rate for DX-52-1 binding at a single site. The ratio of BDX binding
between phosphorylated and unphosphorylated Galectin-3 is more or less constant at 290% ± 14%
(Figure 1-3), which suggests that there is no change in the kinetics of modification upon
phosphorylation. The second possibility is that Ser 6/Ser 12 phosphorylation changes the
conformation of Galectin-3 in such a manner that additional DX-52-1 binding site(s) become
accessible. This would result in each Galectin-3 molecule binding multiple BDX molecules, thus
leading to the observed increase in BDX signal. Due to the fact that the ratio of BDX binding
remains constant the first possibility is rendered unlikely leaving us with the second possibility.
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Figure 1-2: Effect of Phosphorylation on Galectin-3 on BDX Binding
A) Western Blot of Biotinylated DX-52-1 Binding Assay. Lane 1, biotinylated molecular
weight markers; lane 2, galectin-3 control; lane 3, phosphorylated galectin-3
B) Comparison of the Relative Intensity of the BDX signals for Galectin-3 (Gal3-Control) and
Phosphorylated Galectin-3 (Gal3-P). Relative Intensity is defined as the ratio of the directly
measured signal intensity of the sample to the directly measured signal intensity of the
Gal3-Control Sample (SD, n = 3). Difference between Gal3-Control and Gal3-P was
statistically significant (p = 0.0054).
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Figure 1-3: Comparison of BDX Binding Reaction Galectin-3 Control versus Phosphorylated
Galectin-3 at 10 hours and 30 hours
A) Western Blot of Biotinylated DX-52-1 Binding Assay for Galectin-3 Control and
phoshorylated Galectin-3 at 10 hours and 30 hours
B) Comparison of Ratios of BDX Signal Intensity between Phosphoryalted Galectin-3 and
Galectin-3 at 10 hours and 30 hours. Difference between 10 and 30 hours was not
statistically significant
Binding of DX-52-1 to Galectin-3 resulted in a statistically significant reduction in the
interactions of Galectin-3 with six of the Galectin-3 binding partners tested (Figure 1-4). The
strongest reduction by DX-52-1 was found for the interaction of Galectin-3 with Axin, which was
reduced to 54.5% ± 5.90% of the control. The interaction of Galectin-3 with Akt was reduced to
74.8% ± 13.5% of the control. The interaction of K-Ras and Galectin-3 was reduced to 76.1% ±
11.3% of the control. The interaction between Galectin-3 and Gemin-4 was reduced to 77.2% ±
12.9% of the control. The interaction between Galectin-3 and Sufu was reduced to 77.2% ± 10.4%
of the control. DX-52-1 reduced the interaction of Galectin-3 with OCA-B to 84.5% ± 5.90% of
the control. Although these interactions are not completely disrupted by DX-52-1, collectively,
these modest reductions in Galectin-3’s ability to interact with these binding partners could cause
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a substantial effect on the physiology of the cell. Since six out of ten of the binding partners tested
were negatively affected in their ability to bind Galectin-3 by DX-52-1, it is likely that DX-52-1
also inhibits the binding of other Galectin-3-binding proteins to Galectin-3. Moreover, the results
imply that these six proteins interact with Galectin-3 along an overlapping surface of the protein
that encompasses the DX-52-1-binding site, assuming that the DX-52-1 sterically blocks binding
of these Galectin-3-binding proteins. It also implies that, conversely, the remaining four binding
partners tested bind to another part of Galectin-3 outside of the DX-52-1 binding site.
Alternatively, however, DX-52-1 could cause a conformational change in Galectin-3 that
allosterically affects binding of some but not all galecitn-3-binding proteins. In either case, the
results raise interesting and testable hypotheses about how these different Galectin-3-binding
proteins interact with Galectin-3. They also, of course, provide a framework for further studies on
the molecular mode of action of DX-52-1.
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B

Figure 1-4: Effects of DX-52-1 and Phosphorylation on Galectin-3 Interaction with Binding
Partners
A) Western Blots of Galectin-3/Binding Partner Co-Precipitation Assays. Each row shows the
interactions between a binding partner and galectin-3 that has been unmodified (first
column [control]), modified by DX-52-1 (second column), phosphorylated (third column)
or both modified by DX-52-1 and phosphorylation (fourth column). Blots were probed
with mouse anti-galectin-3 antibody and goat anti-mouse antibody conjugated to HRP.
B) Relative Intensity of Interaction of Galectin-3 to Binding Partners. Relative intensity was
defined as the ratio between experimental sample intensity and control sample intensity
(SD, n = 3). DX-52-1 had a statistically significant effect (p < 0.005) for binding of
galectin-3 to Axin, OCA-B, Gemin-4, Akt, and Sufu. Phosphorylation of galectin-3 had a
statistically significant effect for all ten binding partners (p < 0.01 in all cases). Finally,
DX-52-1 treatment resulted in reduced binding of phosphorylated galectin-3 OCA-B and
TCF4 (p < 0.05).
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The interactions between Galectin-3 and all ten of the binding partners tested was affected by
phosphorylation at Ser 6/Ser 12 (Figure 1-4). Phosphorylation at Ser 6/Ser 12 reduced the
interaction between Galectin-3 and K-Ras to 13.3% ± 2.30% of the control. The interaction
between Sufu and Galectin-3 was reduced by phosphorylation to 17.1% ± 13.7% of the control.
The interaction between Galectin-3 and Akt was reduced by phosphorylation to 23.4% ± 16.7% of
the control. The interaction of phosphorylated Galectin-3 with Gemin-4 is 25.5% ± 7.00% of the
control. The interaction between Galectin-3 and CD40 was reduced by phosphorylation to 31.4%
± 16.7% of the control. Phosphorylation reduced the binding of Galectin-3 to β-Catenin to 33.3%
± 8.00% of the control. Phosphorylation of Galectin-3 reduced the interaction between the protein
and TCF4 to 34.0% ± 5.00% of the control. Phosphorylation reduced the binding of Galectin-3 to
Axin to 40.3% ± 23.3% of the control. The interaction of phosphorylated Galectin-3 with OCA-B
was 43.7% ± 6.30% with regard to the control. Phosphorylation reduced the binding of Galectin3 with Bcl-2 to 67.0% ± 7.80% of the control. Since the binding of all ten of the Galectin-3-binding
proteins to Galectin-3 was reduced by phosphorylation of Galectin-3, it is likely that this is a very
broad mechanism of negative control binding of Galectin-3 to other proteins. Furthermore it can
be inferred that compared to DX-52-1 binding, phosphorylation at Ser 6/Ser 12 affects Galectin-3
interaction with its binding partners much more potently. This due to the observation that all
binding partners tested showed reduced interaction with phosphorylated Galectin-3 and the
reductions tended to be of a considerably higher magnitude those observed in the case of DX-521. It can be speculated that if a way to stimulate phosphorylation of Ser 6/Ser 12 in vivo can be
devised than such a way might prove even more promising than DX-52-1 derived anticancer
therapeutic strategies. We observed no statistically significant Ser 6/Ser 12 phosphorylation on the
ability of DX-52-1 to inhibit interaction of Galectin-3 with its binding partners, except in the case
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of OCA-B and TCF4 (Figure 1-4). The interaction between phosphorylated Galectin-3 and OCAB is reduced to 70.2% ± 21.4% by DX-52-1 versus the reduction to 84.8% observed with nonphosphorylated Galectin-3. The interaction between phosphorylated Galectin-3 and TCF4 is
reduced to 65.4% ± 5.50% by DX-52-1 versus the complete lack of statistically significant
difference in the binding of non-phosphorylated Galectin-3. These results imply that only in the
case of these two proteins are there additive or synergistic effects of the two inhibitory
modifications of Galectin-3: the “natural” phosphorylation of Ser 6/Ser 12 on Galectin-3 by CK1
and the “unnatural” alkylation of Galectin-3 by DX-52-1. In the other cases where DX-52-1
inhibits the binding of Galectin-3-binding partners (Akt, Axin, Gemin-4, K-Ras and Sufu), the
inhibitory effect of phosphorylation swamps out the inhibitory effect of DX-52-1 on binding of
Galectin-3 to its binding partners. Since the precise binding site or sites of DX-52-1 have not yet
been mapped, it is possible that DX-52-1 alkylates Ser 6 and/or Ser 12, and therefore is competitive
with phosphorylation at these residues. On the other hand, DX-52-1 may alkylate entirely different
residues. That investigation, however, is beyond the scope of the present study.
In summary, our results suggest that DX-52-1 acts by inhibiting specific interactions of
Galectin-3 with its binding proteins along the discrete surfaces of Galectin-3. Phosphorylation has
a general negative effect on interactions of Galectin-3 with its binding partners. It is clear that
interactions of Galectin-3 with other proteins can be modulated endogenously by phosphorylation
and artificially by small molecules. DX-52-1 and presumably its congeners remain the only known
small-molecule inhibitors of the interaction of Galectin-3 with Galectin-3-binding proteins. They
therefore have considerable potential as tools for the study of Galectin-3 function and as
therapeutic agents for diseases involving Galectin-3 such as oncogenesis.
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Chapter 2
Effect of DX-52-1 on Formation of β-Catenin/Galectin-3/α-Actinin Complex
Introduction
As previously stated Galectin-3 has been demonstrated to perform a critical role in
numerous cell functions and pathogenic processes (1-5). These functions include but are by no
means limited to cell motility, cell proliferation, cell to cell adhesions, cell adhesion to extracellular
matrices, cell differentiation, and pre-mRNA splicing (1-3, 5-8). Galectin-3 has furthermore been
shown to play pivotal roles in cellular apoptosis regulation, metathesis of cancerous cells, as well
as oncogenesis (3, 9, 10). Furthermore Galectin-3 has been detected in a multitude of cellular
locations which include the nucleus, cytoplasm, mitochondria, cell membrane, and even the
extracellular spaces (3, 6-8, 11, 12). Galectin-3 has also been shown to bind with a diverse
multitude of proteins including β-Catenin, OCA-B, K-Ras, and many others (13-17). In Chapter 1
it has been demonstrated that certain covalent modifications undermine the interactions between
Galectin-3 and ten of the aforementioned binding partners. It stands to reason that a covalent
modification that could undermine the interaction between Galectin-3 and its various binding
partners would likely affect a diverse number of cellular processes. This chapter concerns an
investigation of the interactions of Galectin-3 with β-Catenin and α-Actinin, both separately and
simultaneously, due to the fact that these two binding partners respectively play roles in the in the
interaction of the cell surface with the Actinin cytoskeleton, which can have an effect on cell
moltility and metathesis (13, 18-20).

28

β-Catenin is a 92 kDa protein that is a member of the Catenin family of proteins. It is both
a subunit of the cadherin protein complex and has been shown to play a role in the Wnt signaling
pathway (13, 20-23). β-Catenin has been shown to play a role in the developmental systems of
animals as a signal transduction molecule (21). The deregulation of β-Catenin signaling has been
shown to a significant role in oncogenesis (23). β-Catenin is known to interact with F-actin binding
protein α-Actinin though α-Catenin, illustrated in Figure 2-1 (24). However in the course of our
work we have discovered through a series of pull down assays that α-Actinin can bind galectin-3.
This led us to consider the possibility that β-Catenin, an established binding partner of Galectin-3
might bind to α-Actinin through its binding to Galectin-3 as is the case with α-Catenin (24, 25).

Figure 2-1: Interaction between β-Catenin and α-Actinin though α-Catenin providing a link
between cell adhesion protein Cadherin and cytoskeletal protein complex F-actin
α-Actinin is 108 kDa protein that binds to the Actinin cytoskeleton and forms an antiparallel dimer with itself (18). This protein serves the cytoplasmic face of a number of cell
adhesion sites either by binding to the cytoplasmic domain of transmembrane protein such as the
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β subunit of Intergrin or indirectly as is the case for the interaction of α-Actinin with Catherin
though its binding to α-Catenin, which in turn binds to β-Catenin, which binds to the C-terminal
side of Catherin as illustrated in Figure 2-1 (18, 26-28). Due the binding of the Actinin cytoskeleton
by α-Actinin it plays an essential role in cell motility. In the course of this work we have studied
the interaction between α-Actinin and a protein complex comprising β-Catenin and Galectin-3.
We have furthermore studied the ability of DX-52-1 to interfere with the aforementioned
interaction.
DX-52-1 (Figure 1-1) is an analog of quinocarcin that has been shown as an inhibitor of
cellular migration, a key part of the metastatis of tumor cells (29-31). It has been determined that
DX-52-1 targets both Radixin and Galectin-3 (30, 31). DX-52-1 has also been demonstrated to
have a strong effect on cellular proliferation and migration (30, 31). The suggested mechanism by
which DX-52-1 attaches to its targets it the disassociation of its nitrile group followed by the
nucleophilic attack of the resulting carbocation by a nucleophilic amino acid side chain of the
targeted protein (30). Galectin-3 has been revealed to be one of the specific targets of DX-52-1 by
method of a pull down assay involving BDX, (Figure 1-1) and strepadvidin beads (31). Due to the
fact that Galectin-3 interacts with a multitude of proteins that mediate the interaction between cells
and the extracellaur matrix as well as other cells, the inhibition of the cell migration via compound
that binds galectin-3 would be expected (7, 8). The most basic explanation for such an effect being
brought about by DX-52-1 and other small molecules is the direction reduction of the interaction
between Galectin-3 and its binding partners. This might occur though the steric hindrance of
binding partner attachment or via a conformational shift (allostery) in Galectin-3 that reduces its
interaction with its binding partners. In the course of our work we have discovered through a series
of pull down assays of Galectin-3 by an extensive series of its binding partners that DX-52-1 does
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reduce the binding of Galectin-3 in a number of cases but the reductions although statistically
significant, are modest (unpublished results). In an effort to explain the strong effect of DX-52-1
on cellular proliferation and migration detected by Kahasi et al we had hypothesized that due to
the fact that this list Galectin-3 binding partners are associated with a diverse number of cell
functions, reductions of several interactions simultaneously could have a strong cumulative effect
on overall cell function and viability. However the recent findings that will be described in this
work have lead us to formulate a second hypothesis.
In this work we attempt to determine effect of DX-52-1 upon the formation of a three
protein complex consisting of β-Catenin, Galectin-3, and α-Actinin. Furthermore we will also
endeavor to use data concerning the effects of β-Catenin and α-Actinin upon the binding of BDX
to make a rough determination of where on Galectin-3 DX-52-1 bind in relation to where β-Catenin
and α-Actinin bind. We will also attempt to deduce the nature of the effect of DX-52-1 on the
interactions of Galectin-3 with β-Catenin and/or α-Actinin.
Materials and Methods
Expression and Purification of β-Catenin and Galectin-3
Human β-Catenin was expressed as a GST fusion protein by a pGEX-2T-1 vector (donated
by Z.J. Sun of Stanford University) transformed into BL21 (DE3) E. coli cells. Small amounts of
glycerol stock were removed by sterile 200 µl pipette tips to seed cultures in 40 ml of Luria-Bertani
medium containing 1 mM ampicillin (LB-Amp). After growing the cells overnight at 37 °C, the
culture was transferred to a flask containing 4 l LB-Amp, followed by incubation at 37 °C until
the absorbance at 600 nm was between 0.6 and 0.9. Isopropyl β-D-1-thiogalactopyranoside (IPTG)
was added to a final concentration of 1 mM, and the culture was incubated further at 37 °C for 5
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h. The cells were then harvested by centrifugation (4,500 g for 10 min). The cell pellets were stored
overnight at -80 °C. On the next day the cell pellets were thawed at 4 °C over a period of three
hours. The cell pellets were then re-suspended in 140 ml of a lysis buffer consisting of 50 mM Tris
(pH 7.5), 1 mg/ml lysozyme, 1 g/ml leupeptin, 1 g/ml pepstatin A, 0.1 mM
phenylmethylsulfonyl fluoride, 0.1 mM benzamidine and 1% Triton X-100 at 4 °C. The
resuspended cells were homogenized and then incubated on ice for 30 min. The homogenate was
centrifuged at 14,500 g for thirty min. Glutathione-agarose bead slurry (2 ml) was added to the
lysate. The beads were rotated overnight at 4 °C. The beads were centrifuged at 4,500 g for 5 min
and the lysate was discarded. The beads were re-suspended in 40 ml 50 mM Tris (pH 7.5) at 4,500
g for 5 min three times, with removal of supernatant and resuspension of beads between each spin.
The beads were then resuspended in 8 ml of 50 mM Tris (pH 7.5) containing 10 units/ml thrombin.
The beads were rotated overnight at 4°C. The beads were centrifuged at 4,500 g for 5 min, and the
supernatant was transferred to a new tube. Protein concentration was determined by absorbance
measurement at 280 nm (extinction coefficient of 61,950 M-1 cm-1 was estimated using “Richard’s
Protein Calculator” website). The supernatant was concentrated with a YM-10 Centricon filter
until the final protein concentration reached 40 M. The concentrated protein was then aliquoted
and flash frozen by immersion in liquid nitrogen prior to storage at -80 oC. Galectin-3 was prepared
using the protocol described in Chapter 1.
In order to prepare β-Catenin Bearing Beads for use in the pull down assays that are
described later in this section, the protocol is followed up to the step involving the three washes
with 50 mM Tris (pH 7.5). Thereafter the beads are re-suspended in 50 mM Tris (pH 7.5) to a
volume of 1 ml. The beads are then stored at 4 oC until their later use.
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Expression and Purification of α-Actinin
Human α-Actinin was expressed as a histidine tagged protein by a pRSET-6-His-2 vector
transformed into BL21 (DE3) E. coli cells. Small amounts of glycerol stock were picked to seed a
culture in 10 ml of Luria-Bertani medium containing 1 mM ampicillin (LB-Amp). After growing
the cells overnight at 37 °C, the culture was transferred to 1 L LB-Amp followed by incubation at
37 °C until the OD600 was between 0.6 ~ 0.9. IPTG was added to a final concentration of 1 mM
and the culture was further incubated at 37 °C for 5 hours. The cells were then harvested by
centrifugation (4,500 g for 10 minutes). The cell pellets were resuspended in cold 35 ml lysis buffer
containing 50 mM NaH2PO4 (pH 7.5), 500 mM NaCl, 20mM imidazole, 1 mg/ml lysozyme, 1
g/ml leupeptin, 1 g/ml pepstatin A, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 0.1 mM
benzamidine, and 1% Triton X-100. The re-suspended cells were homogenized then incubated on
ice for 30 minutes. The homogenate was then centrifuged at 20,000 g for 30 minutes and the lysate
was retained. Ni-NTA agarose (500 µl) was added to the lysate which was then rotated overnight
at 4°C. The beads were centrifuged at 5,000 rpm for 5 minutes and the lysate was discarded. The
beads were resuspended in 10 ml His Tag Binding Buffer containing 50 mM NaH2PO4 (pH 7.5),
500 mM NaCl and 20 mM imidazole and centrifuged at 4,500 g for 5 minutes with the supernatant
discarded. The aforementioned step was repeated twice. The beads were resuspended in 3 ml His
Tag Elution Buffer containing 50 mM NaH2PO4 (pH 7.2), 500 mM NaCl and 500 mM imidazole.
The beads were vortexed and rotated overnight at 4 oC. The next day the beads were centrifuged
at 4,500 rpm for 5 minutes and the supernatant was retained. The concentration of the protein was
determined by UV absorbance measurement at 280 nm (extinction coefficient of 124,320 M-1 cm1

was estimated using “Richard’s Protein Calculator” website). The supernatant was concentrated
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by YM-10 centricon until the final protein concentration reached 25 M. The concentrated protein
was then aliquoted and flash frozen by immersion in liquid nitrogen prior to storage at -80 oC.
In order to prepare α-Actinin Bearing Beads for use in the pull down assays that are
described later in this section, the protocol is followed up to the step involving the three washes
with His Tag Binding Buffer. Thereafter the beads are re-suspended in His Tag Binding Buffer to
a volume of 1 ml. The beads are then stored at 4 oC until their later use.
Pull Down Assay of Galectin-3/β-Catenin Complex by α-Actinin
On the first day a binding mixture of 1 M β-Catenin and 5 M Galectin-3 as well as a
blank mixture of 1 M β-Catenin alone was incubated overnight at 4 oC. On the second day the
binding mixture and the blank mixture was diluted 10X in water. Equal volumes of α-Actinin
bearing beads (Preparation described earlier in this section) were added to each mixture. These
mixtures were then rotated overnight at 4 oC. On the third day the beads in the binding and blank
mixtures were spun down and the supernatants discarded. The beads were washed three times with
His Tag binding buffer with final volumes being minimized. 40 l SDS-PAGE loading buffer is
added to each set of beads. After boiling for 15 minutes the mixtures were then run on a 12%
polyacrylamide gel at 250 volts for 35 minutes before being transferred to PVDF membrane at 200
mA for 1 hour. The membrane was blocked by a 5% milk/TBS-T solution for 1 hour. Rabbit anti
β-Catenin purchased from Sigma-AldrichTM was diluted 1,000 fold in 5% milk/TBS-T and applied
to the membrane for 1 hour. The membrane was washed three times with TBS-T, 15 minutes per
wash. Goat antirabbit-HRP was diluted 10,000 fold in 5% milk/TBS-T and applied to the
membrane for 1 hour. Once again the membrane was washed three times with TBS-T, 15 minutes

34

per wash. PierceTM ECL Western Blotting Reagent was applied to the membrane for five minutes.
The bands were visualized and then quantified by Bio-Rad Quantity OneTM.
Galectin-3 Binding Assays with β-Catenin and α-Actinin
Two reaction mixtures of Galectin-3 were prepared. The first mixture consisted of 2 µM
Galectin-3 and 1% DMSO and served as the control mixture. The second mixture consisted of 2
µM Galectin-3 and 1 mM DX-52-1. The reaction mixtures were incubated overnight at 4 oC. The
mixtures were diluted 30-fold in water. Equal volumes of β-Catenin bearing glutathione beads
(preparation described earlier in this section) were added to the reaction mixtures which were then
rotated overnight at 4 oC. The beads were then washed three times with 50 mM Tris (pH 7.5). The
beads were then spun down and the supernatants discarded. The beads are washed three times 50
mM Tris (pH 7.5) with final volumes being minimized. 40 l SDS-PAGE loading buffer is added
to each set of beads. After boiling for 15 minutes the mixtures were then run on a 12%
polyacrylamide gel at 250 volts for 35 minutes before being transferred to PVDF membrane at 200
mA for 1 hour. The membrane was blocked by a 5% milk/TBS-T solution for 1 hour. Mouse
antigalectin-3 purchased from Santa Cruz BiotechnologyTM was diluted 1,000 fold in 5%
milk/TBS-T and applied to the membrane for 1 hour. The membrane was washed three time with
TBS-T, 15 minutes per wash. Goat antimouse-HRP was diluted 10,000 fold in 5% milk/TBS-T
and applied to the membrane for 1 hour. Once again the membrane was washed three time with
TBS-T, 15 minutes per wash. PierceTM ECL Western Blotting Reagent was applied to the
membrane for five minutes. The bands were visualized and then quantified by Bio-Rad Quantity
OneTM.
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The Galectin-3 Binding Assay with α-Actinin bearing beads (Preparation described earlier
in this section) was performed in a nearly identical matter as it was to β-Catenin with only two
modifications. The first modification was the beads were allowed to settle by gravity instead using
a centrifuge. The second modification was that the washes were performed with His Tag Binding
Buffer in place of Tris.
BDX Binding Assays
Biotinylated DX-52-1 (BDX) was prepared using methods that were previously described
in the literature (30). Two reaction mixtures were prepared. The first mixture consists of 15 µM
Galectin-3 alone. The second mixture consisted of 15 µM Galectin and 30 µM β-Catenin. The two
mixtures were incubated overnight at 4 oC. The next day BDX was added to both mixtures to a
concentration of 100 µM. The two mixtures were further incubated overnight at 4 oC. Equal
volumes of 2X SDS-PAGE loading buffer were added to each mixture. After boiling for 15
minutes the mixtures were then run on a 12% polyacrylamide gel at 250 volts for 35 minutes before
being transferred to PVDF membrane at 200 mA for 1 hour. The membrane was blocked by a 5%
milk/TBS-T solution for 1 hour. Horse Radish Peroxidase (HRP) Linked Anti-Biotin Antibody
Purchased from Cell SignalingTM was diluted 1,000 fold in milk/TBS-T and applied to the
membrane for 1 hour. The membrane was washed three time with TBS-T, 15 minutes per wash.
PierceTM ECL Western Blotting Reagent was applied to the membrane for five minutes. The bands
were visualized and then quantified by Bio-Rad Quantity OneTM.
The BDX assay described was also performed to determine whether or not α-Actinin
binding to Galectin-3 had any effect upon the ability of DX-52-1 to binding to Galectin-3. The
only difference at the beginning was the composition of the two mixtures prepared. The first
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mixture consists of 15 µM Galectin-3 alone. The second mixture consisted of 5 µM Galectin and
20 µM α-Actinin.
Pulldown Assays of DX-Galectin-3/β-Catenin Complex by α-Actinin
On the first day a DX binding mixture consisting of 1 M Galectin-3 and 1 mM DX-52-1
as well as a control mixture of 1 M Galectin-3 and 1% DMSO were incubated overnight at 4 oC.
On the second day the control and DX binding mixtures were diluted 10X with water. One volume
of 5 M β-Catenin was added to two volumes of the DX binding mixture. 1 volume of 5 M βCatenin was added to two volumes of the control mixture. The mixtures were then incubated
overnight at 4 oC. On the third day the mixtures were diluted 10X with water. Next a blank mixture
consisting of β-Catenin alone was set to a concentration equaling the β-Catenin concentrations of
the control and DX binding mixtures following their dilution with water as previously described.
Equal volumes of α-Actinin bearing beads (Preparation described earlier in this section) were
added to each mixture. These mixtures were then rotated overnight at 4 oC. One the fourth day the
beads in the binding and blank mixtures were spun down and the supernatants discarded. The beads
were washed three times with His Tag binding buffer with final volumes being minimized. 40 l
SDS-PAGE loading buffer is added to each set of beads. After boiling for 15 minutes the mixtures
were then run on a 12% polyacrylamide gel at 250 volts for 35 minutes before being transferred to
PVDF membrane at 200 mA for 1 hour. The membrane was blocked by a 5% milk/TBS-T solution
for 1 hour. Rabbit anti β-Catenin purchased from Sigma-AldrichTM was diluted 1,000 fold in 5%
milk/TBS-T and applied to the membrane for 1 hour. The membrane was washed three times with
TBS-T, 15 minutes per wash. Goat antirabbit-HRP was diluted 10,000 fold in 5% milk/TBS-T and
applied to the membrane for 1 hour. Once again the membrane was washed three time with TBS-
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T, 15 minutes per wash. PierceTM ECL Western Blotting Reagent was applied to the membrane
for five minutes. The bands were visualized and then quantified by Bio-Rad Quantity OneTM. The
binding of the Galectin-3/β-Catenin Complex by α-Actinin in each lane is defined as the intensity
of the β-Catenin band minus the intensity of the β-Catenin band in the lane of the blank mixture
were Galectin-3 was never present. The relative binding of the Galectin-3/β-Catenin Complex in
each lane is summarized by the Equation 1.

𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝐵𝑖𝑛𝑑𝑖𝑛𝑔 =

𝛽𝐶𝑎𝑡 𝐵𝑎𝑛𝑑 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 − 𝛽𝐶𝑎𝑡 𝐵𝑎𝑛𝑑 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 (𝐵𝑙𝑎𝑛𝑘 𝐿𝑎𝑛𝑒)
𝑥 100%
𝛽𝐶𝑎𝑡 𝐵𝑎𝑛𝑑 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 (𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐿𝑎𝑛𝑒) − 𝛽𝐶𝑎𝑡 𝐵𝑎𝑛𝑑 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 (𝐵𝑙𝑎𝑛𝑘 𝐿𝑎𝑛𝑒)

Equation 1: Relative Binding of Galectin-3/β-Catenin Complex to α-Actinin, βCat Band Intensity: Sample involves
DX-52-1 bound Galectin-3, Control Lane: Sample involves Galectin-3 without DX-52-1, Blank Lane: Galectin-3
absent from Sample

Results and Discussion
In the course of our work we have sought to find a link between the ability of DX-52-1 to
bind to Galectin-3 and its ability to reduce both cell migration and proliferation, both observations
made by Kahsai et al. In our earlier work described in Chapter 1 we have observed that the
interaction of Galectin-3 and six out ten of the binding partners we have tested were reduced by
DX-52-1. These reductions were relatively modest. However if this “six out of ten” ratio holds for
the multitude of Galectin-3 binding partners then even modest reductions could yield significant
effects on cell function as a whole. We then sought to determine if DX-52-1 has a greater than
modest effect on the formation of higher order proteins complexes that contain Galectin-3. We
have chosen β-cat/Gal-3/α-act as our test case. The reason for this selection is that both β-Catenin
and α-Actinin both are involved in cell migration which we in the course of our work also study.
We first sought to demonstrate though a pull down assay of β-Catenin by α-Actinin, that
Galectin-3 does in fact provide a link between β-Catenin and α-Actinin, in order to establish the
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importance of Galectin-3 in formation of the β-cat/Gal-3/α-act Complex. Though further pull down
assays we observed the effects of DX-52-1 on the formation of this complex and compared them
to the effects of DX-52-1 on the binding of Galectin-3 to β-Catenin and α-Actinin individually.
Due to the fact that both β-Catenin and α-Actinin are very large compared to Galectin-3 we
postulated that each protein likely covers a high percentage of the surface area of Galectin-3 and
as such their binding sites are likely on opposite sides of Galectin-3 to make such an arrangement
geometrically feasible. Though a series of BDX binding assays we sought to determine whether
the DX-52-1 coincided with β-Catenin or α-Actinin. The two aforementioned observation led us
to propose the layout of the β-cat/Gal-3/α-act Complex shown in Figure 2-2.

Figure 2-2: Proposed Layout of β-Catenin/Galectin-3/α-Actinin Complex, Proposed location of
DX-52-1 binding site relative to β-Catenin is based on the observed ability of that protein to block
the binding of DX-52-1 to Galectin-3, α-Actinin demonstrates no such blocking ability and as such
is suspected of binding to the opposite side of Galectin-3 relative to the β-Catenin/DX-52-1
binding site due the enormous sizes of α-Actinin and β-Catenin relative to the size of Galectin-3
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In the pull down assays of the Galectin-3/β-Catenin Complex by α-Actinin, the results
show that binding Galectin-3 to β-Catenin can in fact provide a link between α-Actinin and βCatenin (Figure 2-3). In the absence of Galectin-3, β-Catenin binding to α-Actinin is reduced to
25.8% ± 3.11% relative to such binding when Galectin-3 and β-Catenin are allowed to form a
complex beforehand. Although the results of the pull down assay does show some α-Actinin/βCatenin binding even the complete absence of Galectin-3, it is quite clear that Galectin-3 does
have a very substantial influence on the ability of β-Catenin to form a complex with α-Actinin. So
it does stand to reason that β-Catenin, Galectin-3, and α-Actinin do in fact form a three protein
complex (β-cat/Gal-3/α-act). The interaction between β-Catenin and α-Actinin is generally
described in the literature to take place through α-Catenin (24, 27). There is as of yet no mention
of an in vivo interaction between β-Catenin and α-Actinin via Galectin-3 in the literature. However
in our attempt to explain the strong cellular effects of DX-52-1 as well as determine a link between
the specific binding of DX-52-1 to Galectin-3 and such effects, the β-Cat/Gal-3/α-Act complex
has provided a useful test case in that DX-52-1 may have larger effect on the formation of higher
order Galectin-3 containing structures than it would on two-protein containing Galectin-3
containing complexes.
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Figure 2-3: Effect of Galectin-3 on the Binding of β-Catenin to α-Actinin
A) Western Blot of Pull Down Assay of β-Catenin by α-Actinin, with Galectin-3 Pre-Bound
to β-Catenin (left lane) vs. β-Catenin alone (right lane)
B) Comparison of the Relative Intensity Relative Intensity of β-Catenin Signal. Relative
Intensity is defined as the ratio of the directly measured signal intensity of the sample to
the directly measured signal intensity of the +Galectin-3 Control Sample (SD, n = 3), The
difference in Binding was statistically significant (p < 0.0001)
The next thing we have sought to probe was the effect of DX-52-1 upon the binding of
Galectin-3 to α-Actinin and β-Catenin individually. The results of the pull down assays we
performed have shown that DX-52-1 does not have a statistically significant effect on the binding
of Galectin-3 and β-Catenin but does in fact have a statistically significant effect on the binding
between Galectin-3 and α-Actinin (Figure 2-4). DX-52-1 seems have reduced the binding of
Galectin-3 and β-Catenin to 92.3% ± 8.14%. More significantly DX-52-1 has reduced the binding
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between Galectin-3 and α-Actinin to 66.4% ± 11.0%, which is in line with the positive results we
have obtained in similar pull down assays with other Galectin-3 binding partners (unpublished
results). DX-52-1 has a modest but significant effect on Galectin-3 binding to α-Actinin and little
if any effect on Galectin-3 binding to β-Catenin. We had initially predicted that any effect that
DX-52-1 has on the formation of the β-cat/Gal-3/α-act complex would be due mostly if not
completely to DX-52-1 undermining the binding between Galectin-3 and α-Actinin. Furthermore
we had predicted that such a reduction would be roughly the same as the reduction of Galectin-3
binding to α-Actinin. However the results we have obtained had completely contradicted those
initial predictions and showed the DX-52-1 has a much more profound effect on the formation of
β-cat/Gal-3/α-act complex than it does on the simple Gal-3/α-act Complex.
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Figure 2-4: Effect of DX-52-1 on the Binding of Galectin-3 to β-Catenin and α-Actinin
A) Western Blots of Pull Down Assays of Galectin-3 by β-Catenin and α-Actinin, Galectin-3
Control (left lanes) and Galectin-3 bound with DX-52-1 (right lanes)
B) Relative Galectin-3 Signal (left lanes [control] vs. right lanes [DX]), Relative Intensity is
defined as the ratio of the directly measured signal intensity of the sample to the directly
measured signal intensity of the Galectin-3 Control (SD, n = 3), DX-52-1 did not show a
statistically significant effect in the pull down of Galectin-3 by β-Catenin, DX-52-1 did
show a statistically significant effect in the pull down of Galectin-3 by α-Actinin (p =
0.014)
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We then proceeded to probe the effect of DX-52-1 on the ability of a β-Catenin/Galectin3 complex to bind to α-Actinin. Our pull down assay has demonstrated that the ability of α-Actinin
to bind to β-Catenin that was in a complex with Galectin-3 bound with DX-52-1 was not
significantly greater that its ability to bind β-Catenin in the complete absence of Galectin-3 (Figure
2-5). We have defined in Equation 1, the net signal for the binding of the β-Catenin/Galectin-3
complex to be the signal over and above the signal for β-Catenin binding α-Actinin in the complete
absence of Galectin-3. The net signal for the binding of α-Actinin by the β-Catenin/Galectin-3
complex when Galectin-3 is bound with DX-52-1 is 5.70% ± 2.73% of the net signal when the βCatenin/Galectin-3 complex is free of DX-52-1. This result stood complete in contrast to what we
had expected to observe based on the results of the individual pull down assays of Galectin-3 by
β-Catenin and α-Actinin. Our previous unpublished results had shown that DX-52-1 had at best
only moderate effects on the ability of Galectin-3 to form two-protein complexes. It now seems
that DX-52-1 may in fact have the ability to severely undermine the formation of higher order
protein complexes involving Galectin-3. Our test case involving β-Cat/Gal-3/α-Act complex
demonstrates that this may indeed be a possibility. The possible effect of DX-52-1 on higher order
Galectin-3 bearing complexes may serve to partially explain why DX-52-1 has a strong cellular
effects and how DX-52-1 binding to Galectin-3 may play a role.
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Figure 2-5: Effect of DX-52-1 on the Binding of β-Catenin/Galectin-3 Complex to α-Actinin
A) Western Blot of β-Catenin Pull Down Assay by α-Actinin, β-Catenin Pre-Bound with
Galectin-3 (left lane) vs. β-Catenin Pre-Bound with DX Bound Galectin-3 (middle lane)
vs. β-Catenin without Galectin-3 (right lane)
B) Relative Net β-Catenin Signal defined as the ratio of the difference between the directly
measured signal intensities of the sample and the Blank Sample [-Galectin-3 and –DX] vs.
the difference between the directly measured signal intensities of the Control Sample
[+Galectin-3 and –DX] (SD, n = 3), Binding DX-52-1 to Galectin-3 showed a statistically
significant effect in the pull down of β-Catenin/Galectin-3 (p < 0.0001), β-Catenin that was
pre-bound with DX-52-1 bound Galectin-3 gave a signal intensity only marginally higher
than β-Catenin in the complete absence of Galectin-3 (+Galectin-3/+DX vs. –Galectin-3/DX)
In addition to probing the effect of DX-52-1 on the binding of β-Catenin and α-Actinin to
Galectin-3, we have also probed the effect of β-Catenin and α-Actinin on the ability of DX-52-1
to bind to Galectin-3. In doing so we have been able to make a rough estimation of where on
Galectin-3 DX-52-1 binds in relation to β-Catenin and α-Actinin. Our BDX binding assay on the
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effect of β-Catenin upon the binding of DX-52-1 to Galectin-3 show such binding to be all but
eliminated (Figure 2-6). When bound to β-Catenin, the binding of BDX by Galectin-3 is reduced
to 2.54% ± 1.23%. The near completeness of this effect suggests that DX-52-1 binding site of
Galectin-3 very likely coincides with the binding site of β-Catenin.

Figure 2-6: Effect of β-Catenin on the binding of DX-52-1 on Galectin-3
A) Western Blot of BDX Assay of Galectin-3, Galectin-3 Control (left lane) vs. Galectin-3
Pre-bound with β-Catenin (right lane)
B) Relative BDX Signal defined as the ratio of the directly measured signal intensity of the
sample to the directly measured signal intensity of the Galectin-3 Control Sample (SD, n
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= 3), β-Catenin reduced the extent of BDX to Galectin-3 by a statically significant amount
(p < 0.0001)
Next we proceeded to determine the effect of α-Actinin on the ability of DX-52-1 to bind
Galectin-3. The BDX binding assay showed there was no reduction of BDX binding to Galectin3 by α-Actinin (Figure 2-7). When in a complex with α-Actinin Galectin-3 binds DX-52-1 96.6%
± 1.41% as much it does when α-Actinin is completely absent, which suggests that the binding site
of α-Actinin does not in any way overlap with the binding site of DX-52-1 unlike β-Catenin.
Serendipitously our BDX Assay had also shown that DX-52-1 also binds to α-Actinin. The
literature had previously shown that in the micromolar range DX-52-1 binds to Galectin-3 and
Radixin (30, 31). It seems that α-Actinin may also be placed upon that list. Due to the fact that βCatenin all but eliminates DX-52-1 binding to Galectin-3 while α-Actinin has practically no effect
at all, it can be reasonably concluded that DX-52-1 binding to Galectin-3 on the roughly same side
as β-Catenin while α-Actinin binds on a completely different side of Galectin. If that conclusion
truly sound it might be further concluded that the effect of DX-52-1 on the binding of Galectin-3
to α-Actinin is likely due to a conformational shift brought about by DX-52-1 since its binding site
the possibility of steric interference is excluded by the aforementioned conclusion, as the DX-521 binding site does not overlap with α-Actinin.
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Figure 2-7: Effect of α-Actinin on the binding of DX-52-1 on Galectin-3
A) Western Blot of BDX Assay on Galectin-3, Galectin-3 Control (left lane) vs. Galectin-3
Pre-bound with α-Actinin (right lane)
B) Relative BDX Signal (left lane vs. right lane) defined as the ratio of the directly measured
signal intensity of the sample to the directly measured signal intensity of the Galectin-3
Control Sample [-α-Actinin] (SD, n = 3), α-Actinin did not reduce the binding of BDX to
Galectin-3 by any statistically significant amount, Also of note it turns out α-Actinin can
itself bind BDX.
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In this work we have shown that Galectin-3 forms a three protein complex with β-Catenin and
α-Actinin. We have further demonstrated DX-52-1 has a much stronger effect on the formation of
the β-Cat/Gal-3/α-Act complex than it does on the formation of two-protein complexes of
Galectin-3 with either β-Catenin or α-Actinin individually thus showing the possibility of DX-521 having a stronger effect on the formation of higher order complexes. This suggests that in the
development of DX-52-1 and similar small molecules as medical treatment may make necessary
the exploration of its effect on Galectin-3 protein complexes with two or more additional proteins.
Our deduction of the general location of the DX-52-1 binding site is somewhat fortuitous
considering difficulty of crystallizing Galectin-3 for x-ray crystallography, which make a direct
determination of the binding site difficult (4). We are confident that further study of Galectin-3
with open up several more avenues of research.
References
1. R. Y. Yang, D.K.H., F. T. Liu (1996). Expression of Galectin-3 Regulates T-cell Growth
and Apotosis. Proc. Natl. Acad. Sci. USA 93, 6737-6742.
2. S. Akhani, P.N.M., H. Inohara, H. C. Kim, A. Raz (1997). Galectin-3: A Novel
Antiapototic Molecule with a Functional BH1 (NWGR) Domain of Bcl-2 Family. Cancer
Res. 57, 5272-5276.
3. D. K. Hsu, R.Y.Y., Z. Pan, L. Yu, D. R. Saloman (2000). Targeted Disruption of the
Galectin-3 Gene Results in Atenuated Pertoneal Responses. Am. J. Pathol. 156, 10731083.

49

4. J. Seetharaman, A.K., R. Slaaby, H. Leffler, S. H. Barondes, J. Rini (1998). X-ray Crystal
Structure of the Human Galectin-3 Carbohydrate Recognition at 2.1 Angstrom Resolution.
J. Biol. Chem. 273, 13047-13052.
5. H. Inohara, S.A., A. Raz (1998). Galectin-3 Stimulates Cell Proliferation. Exp. Cell. Res.
245, 294-302.
6. S. F. Dagher, J.L.Wang., R. J. Paterson (1995). Indentification of galectin-3 as a factor in
pre-mRNA Splicing. Proc. Natl. Acad. Sci. USA 92, 1213-1217
7. J. Ochieng, M.L.B., P. Warfield (1998). Regulation of Cellular Adhesion to Extracelluar
Matrix Proteins by Galectin-3. Biochem. Bioph. Res. Co. 246, 788-791.
8. H. Inohara, S.A., K. Koths, A. Raz (1996). Interactions between Galectin-3 and Mac-2
Protein Mediate Cell-Cell Adhesion. Cancer Res. 56, 4530-4534.
9. Y. Takenaka, T.F., A. Raz (2004). Galectin-3 and Metastasis. Glycoconjugate J. 19, 543549.
10. T. Yoshii, T.F., Y. Honjo, H. Inohara, H. C Kim, A. Raz (2002). Galectin-3
Phosphorylation Is Required for Its Anti-apototic Function and Cell Cycle Arrest. J. Biol.
Chem. 277, 6852-6857.
11. F. Yu, R.L.F., A. Raz, H. C. Kim (2002). Galectin-3 Translocates to Perinuclear
Membranes and Inhibits Cytochrome c Release from Mitochondria: A role for Synnexin
in Galectin-3 Translocation. J. Biol. Chem. 277, 15819-15827.
12. B. Moon, Y.L., P. Battle, J. Jessup, A. Raz, H. C. Kim (2001). Galectin-3 Protects Human
Breast Cancer Cells Against Nitric Oxide Induced Apotosis: Implication of Galectin-3
Function During Metathesis. Am. J. Pathol. 159.

50

13. P. M. Weinberger, B.A., C. Gourin, W. H. Moretz, R. J. Bollag, B. Wang, Z. Lui, J. R. Lee,
D. J. Terris (2007). Association of Nuclear, Cytoplasmic Expression of Galectin-3 with
Beta-Catenin/Wnt-Pathway Activation in Thyroid Carcinoma. Arch. Otolaryngol. Head
Neck Surg. 133, 503-510.
14. 14 G. A. Rabinovich, M.A.T., S. S. Jackson, G. R. Vasta (2007). Function of Cell Surface
Galectin-Glycoprotein Lattice. Curr. Opin. Struc. Biol. 17, 513-520.
15. K. Geihl (2005). Onocogenic Ras in Tumor Progression and Metastasis. Biol. Chem. 386,
193-205.
16. J. Dumic, S.D., M. Flogel (2006). Galectin-3: An Open Ended Story. Biochim Biophys
Acta 1760, 616-635.
17. A. Krzeslak, A.L. (2004). Galectin-3 as a Multifunctional Protein. Cell Mol Biol Lett 9,
305-328.
18. C. Otley, O.C. (2004). Alpha Actinin Revisted: A Fresh Look at an Old Player. Cell Motil
Cytoskel 58, 104-111.
19. B. Sjoblom, A.S., K. Carugo (2008). Alpha Actinin Structure and Regulation. Cell Mol.
Life Sci. 65, 2688-2701.
20. T. P. Hill, D.S., M. M. Taketo, W. Birchmeier, C. Hartmann (2005). Canonical Wnt/BetaCatenin Signaling Prevents Osteoblasts from Differentiating in Chondrocytes. Develop.
Cell 8, 727-738.
21. P. Polakis (1999). The Oncogenic Activation of Beta-Catenin. Curr. Opin. Genet. Dev. 9,
15-21.

51

22. C. Kraus, T.L., J. Hulsken, J. Behrens, W. Birchmeier, K. Grzeschik, W. Ballhausen
(1994). Localization of the Human Beta-Catenin Gene (CTNNB1) to 3p21 a Region
Implicated in Tumor Development. Geonomics 23, 272-274.
23. P. J. Morrin (1999). Beta-Catenin Signaling and Cancer. Bioassays 12, 1021-1030.
24. F. Drees, S.P., S. Yamada, J. Nelson, W. I. Weiss (2005). Alpha-Catenin Is a Molecular
Switch That Binds E-Cadherin-Beta-Catenin and Regulates Actin Filament Assembly. Cell
123, 903-915.
25. T. Shimura, Y.T., V. Hogan, A. Kikuchi, A, Raz (2004). Galectin-3, a Novel Binding
Partner of Beta-Catenin. Cancer Res. 64, 6363-6367.
26. C. Otley, G.B.V., K. Burridge, B. W. Erickson (1993). Mapping of Alpha-Actinin Binding
Site With the Beta-1 Integrin Cytoplasmic Domain. J. Biol. Chem. 268, 21193-21197.
27. K. A. Knudsen, A.P.S., K. R. Johnson, M. J. Wheelock (1995). Interaction of AlphaActinin with the Cadherin/Catenin Cell-Cell Adhesion Complex via Alpha-Catenin. J. Cell
Biol. 130, 67-77.
28. T. D. Pollard, P.T., D. L. Rimm, D. P. Birchell, R. C. Williams, J. Sinard, M. Sato (1986).
Characterization of Alpha-Actinin From Acanthamoeba. Cell Molt. and the Cytoskel. 6,
649-661.
29. J. Plowman, D.J.D., V. L. Narayanan, B. J. Abbott, H. Saito, T. Hirata (1995). Efficacy of
the Quinocarmycin KW2152 and DX-52-1 Against Human Melanoma Lines Growing in
Culture and in Mice. Cancer Res. 55, 862-867.
30. A. W. Kahasi, S.Z., D. J. Warhop, W. S. Lane, G. Fenteany (2006). Quinocarmycin Analog
DX-52-1 Inhibits Cell Migration and Targets Radixin, Disrupting Interactions of Radixin
with Actinin and CD44. Chem. & Biol. 13, 973-983.

52

31. A. W. Kahasi, J.C., H. U. Kaniskan, P. P. Garner, G. Fenteany (2008). Analogs of
Tetrahydroisoquinoline Natrual Products Thats Inhibit Cell Migration and Target Galectin3 Outside Its Carbohydrate-Binding Site. J. Biol. Chem. 283, 24534-24545.

53

Chapter 3
Mapping of DX-52-1 Binding Peptide on Galectin-3
Introduction
Throughout the literature Galectin-3 has been shown to play a role in a number of cellular
and pathogenic processes (1-8). The data provided in the previous two chapters have shown the
quinocarcin analog DX-52-1 has a demonstrable effect on the ability of Galectin-3 to interact with
its binding partners. Furthermore DX-52-1 has been shown to exhibit inhibitory properties on both
cell proliferation and migration. The link between these two properties and Galectin-3 was
established by Kahsai et al and is further supported by the results that will be described and
discussed in Chapter 4 (9). In order to properly understand the mechanism by which the interaction
between DX-52-1 and Galectin-3 exerts its effects on binding partner interaction, cell proliferation
and cell migration, it is important to ascertain the exact position on Galectin-3 to which DX-52-1
binds.
Normally this determination would be accomplished by running DX-52-1 bound Galectin3 alongside control Galectin-3 on a polyacrylamide gel followed an in-gel tryptic digestion for
submission to LC-MS/MS analysis. However in the case of Galectin-3 this has proven problematic.
In fact a comparison of the mass spectra of even undigested DX-52-1 bound Galectin-3 and control
Galectin-3 show absolutely no mass shift due to DX-52-1 (Figure 3-1). It is clear that at some point
in either sample preparation for MS or the MS process itself the bound DX-52-1 is somehow lost.
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Figure 3-1: MALDI-TOF ES+ data shows (A) m/z of 26.3 kDGalectin-3 untreated and (B) m/z of
26.3 kD DX-52-1 treated Galectin-3
Alanine scanning via site directed mutagenesis was selected as an alternative strategy to
mass spectrometry. Alanine scanning essentially involves creating a series of mutant proteins, each
of have a residue of interest substituted with alanine for the purpose of determining those residues’
impact on the function of a protein (10-14). Assuming the mechanism proposed by Kashai et al is
in fact correct then any Galectin-3 residue with a nucleophilic side chain is a possible candidate.
Twenty seven such candidates were identified on CRD alone. The project described in this chapter
concerns both the determination on the cause of the loss of DX-52-1 binding with Galectin-3 and
the development of a method to reduce the number of candidate residues for alanine screening.
The DX-52-1 binding residue can be localized in terms of protein sequence by isolating
the tryptic fragment that contains that residue (Figure 3-2). It is worth noting that the cleavage sites
for tryptic digestion of Galectin-3 are all to be found in the second half of the protein, essentially
the CRD portion (Figure 3-3). If it had turned out that DX-52-1 binds to the ND section, it would
have been necessary to use a different protease. It was hypothesized that the reason for DX-52-1
being lost by Galectin-3 was due to the final step in the MS sample preparation which involves
acidification. This forms the cornerstone of the proposed DX binding peptide isolation method in
this chapter. The first step is binding BDX to Galectin-3. The second step is binding the
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BDX/Galectin-3 to streptavidin agarose beads. Any protein that fails to bind to the beads is washed
away. The third step involves the beads bearing Galectin-3 being subjected to trypsin proteolysis.
Any tryptic fragment that is not direct bound to the BDX would break away as a result. In the
fourth step the beads would then be treated with formic acid and presumably the bond between
BDX and the Galectin-3 peptide bound to it would be broken. The beads would be removed by
centrifugation and the peptide containing the DX-52-1 binding residue should remain in the
supernatant. The sequences of this peptide would be determined by MS/MS. This would reduce
the list of DX-52-1 binding residue candidates significantly.
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Figure 3-2: Scheme of DX-52-1 Binding Peptide Isolation Protocol. Streptavidin beads bind the
biotin component of BDX bound Galectin-3. After Trypsin digestion only the fragment directly
attached to BDX remains linked to the Streptavidin bead. Formic acid treatment breaks the bond
between that and BDX. The former BDX bound peptide is then sequenced via MS/MS.
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Materials and Methods
Preparation of Galectin-3 and CRD
Galectin-3 was prepared for this project using the same protocol that was described in the
Materials and Methods section of Chapter 1. CRD, which was expressed using a pGEX-6P-1
plasmid, was expressed using a protocol similar to that which was employed for Galectin-3 but
with a few variations. The first variation is the time in which the expressing cells were induced
with IPTG was 3 hours instead of the usual 5 hours. The second variation is that the protease
PreScissionTM (Purchased from GE Healthcare) was used to cleave CRD from its GST tag instead
of Thrombin.
BDX Assay for CRD
On the first day a reaction mixture consisting of 100 µM CRD and 1 mM BDX was
prepared. The reaction mixture was then incubated at 4 oC overnight. On the second day equal
volumes of 2X SDS-PAGE loading buffer was added to the mixture. After boiling for 15 minutes
the mixture was then run on a 12% polyacrylamide gel at 250 volts for 35 minutes before being
transferred to PVDF membrane at 200 mA for 1 hour. The membrane was blocked by a 5%
milk/TBS-T solution for 1 hour. Horse Radish Peroxidase (HRP) Linked Anti-Biotin Antibody
Purchased from Cell SignalingTM, was diluted 1,000 fold in milk/TBS-T and applied to the
membrane for 1 hour. The membrane was then washed three time with TBS-T, 15 minutes per
wash. PierceTM ECL Western Blotting Reagent was applied to the membrane for five minutes. The
bands were visualized and then quantified by Bio-Rad Quantity OneTM.
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BDX/Acid Assay for Galectin-3
On the first day a reaction mixture consisting of 25 µM Galectin-3 and 200 µM BDX was
prepared. The reaction mixture was then incubated at 4 oC overnight. On the second day the
reaction mixture was divided into two samples. Formic acid to a concentration of 7% was added
to one of the samples. An equivalent volume of water was then added to the other sample. The two
samples were then incubated overnight at 4 oC. On the third day the two samples were subject to
the same western blot procedure that was employ for CRD as described in the previous paragraph.
Catch and Release Test for Galectin-3
On the first day a reaction mixture consisting of 25 µM Galectin-3 and 200 µM BDX was
prepared. This reaction mixture was then incubated at 4 oC overnight. On the second day an equal
volume of streptavidin-agarose beads were added to the reaction mixture. The reaction mixture
was rotated overnight at 4 oC. On the third day the beads were centrifuged. The supernatant was
designated “Supernatant 1” and stored for later use. The beads were then washed three times with
water and the final volume was minimized. The beads were then re-suspended in 7% formic acid.
The beads were then rotated overnight at 4 oC. On the fourth day the beads were centrifuged and
the supernatant removed was designated “Supernatant 2” Equal volumes of SDS-PAGE loading
buffer were added to Supernatant 1 and Supernatant 2. The beads were mixed with 20 µl of SDSPAGE loading buffer. After boiling for 15 minutes the mixtures were then run on a 12%
polyacrylamide gel at 250 volts for 35 minutes before being transferred to PVDF membrane at 200
mA for 1 hour. The membrane was blocked by a 5% milk/TBS-T solution for 1 hour. Mouse
antigalectin-3 purchased from Santa Cruz BiotechnologyTM was diluted 1,000 fold in 5%
milk/TBS-T and applied to the membrane for 1 hour. The membrane was washed three times with
TBS-T, 15 minutes per wash. Goat antimouse-HRP was diluted 10,000 fold in 5% milk/TBS-T
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and applied to the membrane for 1 hour. Once again the membrane was washed three times with
TBS-T, 15 minutes per wash. PierceTM ECL Western Blotting Reagent was applied to the
membrane for five minutes. The bands were visualized and then quantified by Bio-Rad Quantity
OneTM.
DX-52-1 Binding Peptide Isolation
On the first day three identical reaction mixtures consisting of 25 µM Galectin-3 and 200
µM BDX were prepared. These reaction mixtures were then incubated at 4 oC overnight. On the
second day equal volumes of streptavidin beads were added to each reaction mixture. The reaction
mixtures were rotated overnight at 4 oC. On the third day the mixtures were centrifuged and the
beads were retained. Each set of beads was re-suspended in 4M-urea/25 mM ammonium
bicarbonate and rotated at room temperature for 15 minutes. The beads were centrifuged and the
supernatant was discarded. The two aforementioned steps were repeated twice and the final
volumes were all minimized. The beads were re-suspended in 10 mM DTT/25 mM ammonium
bicarbonate and rotated at 37 oC for 45 minutes. The beads were then centrifuged and the
supernatant was discarded. The beads were washed with 4M urea/25 mM ammonium bicarbonate
as previously described. The beads were then re-suspended in 20 mM Iodacetimide and rotated at
room temperature in the dark for 1 hr. The beads were once more washed with 4M urea/25 mM
ammonium bicarbonate as previously described. The beads were then resuspened in 12.5 ng/µl
Trypsin/40 mM ammonium bicarbonate. The beads were then rotated overnight in the dark at 37
o

C. On the fourth day the beads were centrifuged and the supernatant was discarded, the beads

were washed with water three times and the final volumes were all minimized. Each set of beads
was re-suspended in 7% formic acid. The beads were then rotated overnight at 4 oC. On the fifth
day the beads were spun down and the supernatants were retained. The three supernatants were
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pooled together and the solvent was removed by spin vac. The residue was then re-suspended in
20 µl 0.1% formic acid. The sample was submitted for LC-MS/MS analysis. The amino acid
sequence derived from the mass spectrometry data was then compared to the sequences of the
predicted tryptic fragments for CRD (Figure 3-3).

Figure 3-3: Trypsin Cleavage Map of Galectin-3 CRD Domain
Results and Discussion
It was determined by BDX assay that DX-52-1 binds to the CRD region of Galectin-3
(Figure 3-4). It is worth noting that the amount of both BDX and protein required to generate a
substantial signal is higher than what is required in the case of full length Galectin-3. The BDX
assay for CRD involved 100 µM CRD and 1 mM BDX. In the case of full length Galectin-3 the
BDX assay will yield a detectable signal even when the concentration of Galectin-3 and BDX are
as low as 12.5 µM and 25 µM respectively (Fenteany Group Unpublished Results). The ND region
however showed no BDX binding signal even at concentrations higher than those employed for
CRD. It can therefore be reasonably concluded that DX-52-1 binds to the CRD region of Galectin61

3. It can be further concluded that although the ND region itself does not bind DX-52-1 it does
play a role in the binding of DX-52-1 to Galectin-3. The CRD of Galectin-3 has a total of 27 amino
acids that have nucleophilic side chains. These residues include Y118, T133, T137, K139, H158,
C173, T175, K176, S118, S194, K196, K199, H208, K210, H217, Y221, H223, K226, K227,
S232, K233, S237, T243, S244, S246, Y247, and T248.

Figure 3-4: BDX Assay of CRD, 100 µM Galectin-3 CRD was incubated with 1 mM BDX
overnight. This mixture was subjected to a western blot. The membrane was probed using
antibitin-HRP antibody. Result indicates CRD domain of Galectin-3 binds BDX. Assay was
performed on N-terminal Domain of Galectin-3. Those results (not shown) were negative.
Formic Acid treatment of BDX bound Galectin-3 results in a near total loss of BDX signal
(Figure 3-5). The result implies that acidification causes the BDX and presumably DX-52-1 to
break away from Galectin-3. This effect was observed when the formic acid concentration was as
little as 7%. It is also noteworthy that a similar effect was observed with BDX bound Radixin,
which suggests that the observed effect is due to DX-52-1 alone (Fenteany group Unpublished
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Results). The protocol for MS sample preparation of DX-52-1 bound Galectin-3 has formic acid
concentrations going as high as 50%. Although this formic acid induced loss of DX-52-1 poses an
inconvenience it also provided a way to shorten the list of candidate Galectin-3 residues that would
have to be tested through alanine scanning.

Figure 3-5: Effect of Formic Acid Treatment of DX-52-1 Bound Galectin-3. 25 µM Galectin-3 +
200 µM BDX reaction mixture was incubated overnight and split into two samples. Formic acid
was added to the “Formic Acid” Sample to a concentration of 7%. The Formic Acid Sample and
Control Samples were subjected to a western blot and the membrane was probed with antibiotinHRP. Biotin signal is severely reduced in the Formic Acid Sample lane.
In the course of developing the DX-52-1 binding peptide isolation protocol proposed in
this chapter a “Catch and Release Test” was performed to verify that formic acid does in fact break
the bound between Galectin-3 and DX-52-1. The western blot result obtained at the end of the
experiment shows that Galectin-3 was liberated from the streptavidin bead it was bound to through
BDX (Figure 3-6). The 7% formic acid used is nowhere near sufficient to break the bound between
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streptavidin and the biotin of BDX. Due to this result it was concluded that formic acid should be
able to successfully free the DX-52-1 binding peptide from streptavidin beads as well.

Figure 3-6: Catch and Release Test of Galectin-3. BDX bound Galectin-3 was captured by
suspending Streptavidin beads to a reaction mixture of 25 µM Galectin-3 and 200 µM BDX. The
beads were spun down by centrifugation. The beads were then suspended in 7% formic acid.
“Supernatant 2” is the supernatant of that suspension. Sample of Supernatant 2 and Streptavidin
beads were subjected to a western blot and probed with mouse antigalectin-3 primary antibody
and antimouse-HRP secondary antibody.
The mass spectrometry results obtained by the University of Connecticut Chemistry
Department Mass Spectrometry Facility concerning the sample obtained through the DX-52-1
binding peptide isolation protocol showed the detection of a single peptide with a mass of 1641.00
Daltons. The sequence as determined by MS/MS was MLITILGTVKPNANR [Residues 130-144]
(Figure 3-7). This peptide sequence is consistent with the peptides found in the tryptic cleavage
map of CRD (Figure 3-3). This amino acid sequence has a total of three of the candidate amino
acids out the previously mentioned twenty-seven (T133, T137, and K139). This should make the
alanine scanning project an easier undertaking than it might otherwise be.
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Figure 3-7: ESI-MS/MS spectrum of DX-52-1/Galectin-3 Binding Petide MLITILGTVKPNAN
(residues 130-144, m/z = 1656 Da), Sequence determined via differences in the m/z of molecular
ion fragments of MLITILGTVKPNAN separated by the second mass analyzer
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Chapter 4
Structure-Activity Relationship Study of DX-52-1
Introduction
Cell motility is a fundamental biological process, that is integral to key processes in
mammalian organisms, such as embryonic development, tissue repair, immune response,
inflammation and angiogenesis (1, 2) Furthermore cell migration also plays important role in
cancer cell invasion and metastasis (3, 4). The rates of cell motility along with cell proliferation
are both very important factors in determining the progression of cancers so it stands to reason that
any small molecule that can inhibit one or both of these processes might form the basis for an anticancer treatment. The small molecule might accomplish this task by binding to a protein that is
involved in the aforementioned processes and affect its interaction with other proteins involved in
such processes. Galectin-3 which is involved in a great number of cellular functions including
proliferation and motility is such protein (5-10).
The small molecule studied for the purpose of this project is DX-52-1, (Figure 1-1) an
analog of quinocarcin that binds Galectin-3, has been demonstrated to be an inhibitor of cell
migration, a key part of tumor cell metastasis (11-13). Furthermore DX-52-1 has also been shown
to inhibit cell proliferation to varying extents in a number of mammalian cancer cell lines
(Fenteany Group Unpublished Results). DX-52-1 has also been shown to bind Radixin, member
of the Ezrin-Radixin-Moesin (ERM) family of proteins (13, 14). The ERM family plays a role in
the structure of the cell cytoskeleton and may also play a role in cancer progression (13, 14).
Radixin was also shown to play a role in cell migration via the counteracting effects of Radixin
over-expression upon the anti-migratory effects of DX-52-1 and furthermore DX-52-1 has been
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shown to be a potent inhibitor of the protein-protein interaction between Radixin and its binding
partners (13). It is for these reasons that Radixin will be studied alongside Galectin-3.
The objective of this project is to determine the impact of modifying certain functional
groups of the DX-52-1 molecule (Figure 4-1). These functional group modifications include the
esterification of the hydroxyl group with an acetate (BO1-95), the placement of a bromine atom
on the phenyl ring in the para position to the methoxy group (BO2-7), both of the aforementioned
modifications on the same molecule (BO1-180), the removal of the nitrile group (1X-108), the
substitution of the nitrile group with a ethynyl-TMS group (1X-140), and the replacement of the
carboxyl group with a methyl hydroxyl group (1X-141). The impacts that were examined include
the Galectin-3 and Radixin binding properties of the aforementioned DX-52-1 derivatives vs. the
parent compound as well as the anti-migratory and anti-proliferation effects of the derivatives vs.
the parent compound.
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Figure 4-1: Structures of DX-52-1 and its Assorted Derivatives Prepared by Nicholas Eddy
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One particular cancer cell line was chosen for these structure-activity relationship (SAR)
studies. That cell line is MDA-MB-435, which is derived from malignant breast tumors (15). The

rationale for this decision was that DX-52-1 had demonstrated the strongest overall antiproliferation effects upon MDA-MB-435 in terms of dose response as compared to other cell lines
tested (Fenteany Group Unpublished Results). Furthermore MDA-MB-435 also showed a great
deal of sensitivity to DX-52-1 in terms of cell migration with regard to dose response (Fenteany
Group Unpublished Results). It was reasoned if any of the functional group modifications had a
negative impact on the anti-migratory and/or the anti-proliferation effect of DX-52-1 then those
effects should be more pronounced in the proliferation and migration assays performed on MDAMB-435 than any of the other cell lines that were studied.
Materials and Methods
Galectin-3, Radixin, BDX, and DX-52-1 Analogs
The Galectin-3 used in the experiments described in this chapter was prepared used the
protocol described in the Materials and Methods section in Chapter 1. The Radixin used was
obtained from frozen aliquots stored at -80οC. These aliquots were prepared at an earlier date by
former Fenteany Research Group Member Alem Kahsai. The BDX and DX-52-1 analogs were
synthesized by Fenteany Research Group Member Nicholas Eddy.
DX-52-1 Analog Competition Assays for Galectin-3 and Radixin
On the first day five reaction mixtures were prepared for Galectin-3. All reaction mixtures
contained 20µM BDX and 1.5 µM Galectin-3. The DX Mixture contained 500 µM DX-52-1. The
BO1-95, BO1-180, BO2-7, 1X-108, 1X-140, and 1X-141 mixtures each contained 500 µM of the
corresponding DX-52-1 analog. The control mixture contained neither DX-52-1 nor any of its
71

analogs. The reaction mixtures were incubated at 4 οC overnight. On the second day the reaction
mixtures were run on 12% SDS-PAGE gel at 250 V for 35 minutes before being transfer to a
PVDF membrane at 200 mA. The membrane was blocked with a 5% milk/TBS-T solution for 1
hour. Antibiotin-HRP antibody was applied to the membrane for 1 hour. The membrane was
washed three times with TBS-T, 15 minutes per wash. Pierce ECL Western Blotting Reagent was
then applied to the membrane for 5 min. Band intensity was quantified with Bio-Rad Quantity One
software. In the case of Radixin the protocol is similar with 1.2 µM Radixin being substituted for
Galectin-3.
The relative competition of each DX-52-1 analog was defined by its ability to reduce the
intensity of the BDX band relative to the ability of DX-52-1 to do the same. The relative percent
competition was computed using the Normalized Relative Competition Equation (Equation 2). This
equation is defined in such a way that if the DX-52-1 analog band intensity is equal to the band
intensity in the control lane, which would indicate no competition with BDX then the relative
percent competition works out to 0%. If DX-52-1 analog band intensity is equal to the band
intensity in the DX lane, indicating BDX completion equal to DX-52-1 then the relative percent
competition works out to 100%.

Equation 2: Normalized Relative Competition Equation. “DX Band” refers to BDX western blot
signal intensity of sample with DX-52-1 in competition with BDX. “Analog Band” refers to BDX
western blot signal intensity of sample with a DX-52-1 derivative in competition with BDX.
“Control Band” refers to BDX western blot signal intensity of sample with neither DX-52-1 nor
any of its derivatives in competition with BDX.
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Cell Cultures
MDA-MB-435 cells were cultured in a growth medium containing D-MEM (Dulbecco's
Modified Eagle Medium) and 10% FBS (Fetal Bovine Serum) with 5% CO2 in a humidified tissue
culture incubator. Early passages of cells cultured from frozen stock cultures were used in all
experiments. Main cultures were grown in 75-cm2 tissue culture flasks with medium changed
every two days. When the cultures reached 90% confluence, the cells were gently washed twice
with

phosphate

buffered

saline

(PBS),

and

treated

with

a

solution

of

trypsin/ethylenediaminetetraacetic acid (EDTA) in PBS to detach cells from the flasks. After cells
were detached, an equal volume of fresh medium was added to inhibit the trypsin activity. The
cells were re-suspended in media and cell density was determined with a hemacytometer. Cells
were replanted in fresh medium in new tissue culture flasks for continued culture and multi-well
tissue culture plate for experiments. In the case of the cell proliferation assays to be described
below the suspension was diluted to a concentration of 40,000 cells per milliliter. 100 µl of the
cell suspension is added to each well of 96-well plates (except for the first column which were left
empty) which were then placed in the incubator. In the case of the wound closure assays to be
described below 500 µl of cell suspension was added to each well of 24-well plates which were
then placed in the incubator.
Wound Closure Assays
The 24-well plates described previously were incubated until cells were confluent and
forming a monolayer as determined by light microscope. The media in the wells of the other plates
were decanted and replaced with fresh media containing varying concentrations of DX-52-1
analog. Different plates were designated for different DX-52-1 Analogs and the columns on each
plate were each designated for a different concentration (control (0 nM [control], 62.5 nM, 125
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nM, 250 nM, 500 nM and 1 µM). The plates were then incubated for an additional 30 minutes.
Wounds were scratched into the center of each well using disposable pipette tips. These wounds
were photographed using a digital camera mounted on a light microscope. The plates were then
incubated over a 48 hour period with the wounds in each well being photographed at 3 hrs, 6 hrs,
9 hrs, 12 hrs, 24 hrs, and 48 hours. The perimeter of each would was measured in each photograph
by using ImageJ software. The percent wound closure at each time point was defined as (1 – wound
size/initial wound size) * 100%.
Cell proliferation Assays
The 96-well plates described previously were incubated for 24 hours. The cell population
of one plate was counted with the Cell Counting Kit-8 (Dojindo), a tetrazolium salt-based assay,
with an absorbance plate reader (SpectraMax Plus384, Molecular devices) based on manufacturer's
protocol. The media in the wells of the other plates were decanted and replaced with fresh media
containing varying concentrations of DX-52-1 analog. Different plates were designated for
different DX-52-1 Analogs and the columns on each plate were each designated for a different
concentration (control (0 nM [control], 62.5 nM, 125 nM, 250 nM, 500 nM and 1 µM). The plates
were further incubated for 48 hours. The cell populations of each plate were quantified with the
Cell Counting Kit-8 (Dojindo) as previously described. The effects of the DX-52-1 analogs on
cells proliferation were computed by dividing the average cell counts in each column of each plate
by the average of cell count of the plate incubated only 24 hours before quantification. The ratios
indicated the effect of the various DX-52-1 analogs on cell proliferation over a 48 hour period.
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Results and Discussion
In the competition assays of DX-52-1 and its assorted derivatives vs. BDX in regards to
Galectin-3, none of the derivatives had band intensities their lanes equivalent to the band intensity
present in the control lane (Figure 4-2A). This would indicate that none of the functional group
modifications completely prevented competition and therefore all the derivatives were able to bind
to Galectin-3. However most of the band intensities of the derivatives were greater than the band
intensity in the DX-52-1 lane (Figure 4-2A) which suggests in most of the functional modifications
caused reductions in competition as computed by Equation 2 (Figure 4-2B) and most likely binding
ability as well. The derivative BO1-95 which involves a substitution of the DX-52-1 hydroxyl
group with an acetyl group, exhibited a competition of 47.7% ± 28.6% (p value < 0.05) when
compared with DX-52-1. The derivative BO2-7 which involves the placement of a bromine atom
on the DX-52-1 phenyl ring in the para position to the methoxy group, showed no statically
significant reduction in competition as compared with DX-52-1. The derivative BO1-180 which
combines the functional group modifications of BO1-180 and BO2-7, exhibited a competition of
35.7% ± 1.88% (p value < 0.001). In the case of the derivative 1X-108 which involves the removal
of the nitrile group from DX-52-1 showed a competition of 3.76% ± 4.08% (p value < 0.001). The
derivative 1X-140 which has the DX-52-1 nitrile group substituted with an ethynyl-TMS group
showed a competition of 4.50% ± 1.31% (p value < 0.001). The derivative 1X-141 which has the
DX-52-1 carboxyl group substituted reduced to a methyl hydroxyl group showed a competition of
3.51% ± 1.10% (p value < 0.001). The results of the BDX competition assay of DX-52-1 and its
derivatives shown a similar pattern in the case of Radixin (Figures 4-3A and 4-3B). BO1-180 and
BO1-95 respectively show competitions of 25.6 ± 8.16% and 52.5% ± 1.14% (both p values <
0.001) relative to DX-52-1. BO2-7 showed no a relative competition that did not differ from DX-
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52-1 in a statistically significant way. The relative competitions of 1X-108, 1X-140, and 1X-141
were respectively 22.2% ± 12.7%, 16.5% ± 6.37%, and 22.8% ± 14.5% (p value < 0.001 in all
three cases).

Figure 4-2: BDX Competition Assays of DX-52-1 and its Assorted Derivatives with Regard to
Binding Galectin-3. Measurements were made by western blots using antibiotin-HRP to probe for
BDX
A) BDX Signal Intensity as a Percentage of the BDX Signal Intensity in the Control Lane
Relative Intensity is defined as the ratio of the directly measured signal intensity of the
sample to the directly measured signal intensity of the Galectin-3 Control Sample (SD, n
= 3).
B) Percent Competition Relative to DX-52-1 as Defined by Equation 2 (SD, n = 3). All
analogs with the exception of BO2-7 showed statistically significant less competition with
BDX when compared to DX-52-1 (p < 0.05).
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Figure 4-3: BDX Competition Assays of DX-52-1 and its Assorted Derivatives with Regard to
Binding Radixin. Measurements were made by western blots using antibiotin-HRP to probe for
BDX
A) BDX Signal Intensity as a Percentage of the BDX Signal Intensity in the Control Lane
Relative Intensity is defined as the ratio of the directly measured signal intensity of the
sample to the directly measured signal intensity of the Radixin Control Sample (SD, n =
3).
B) Percent Competition Relative to DX-52-1 as Defined by Equation 2 (SD, n = 3). All
analogs with the exception of BO2-7 showed statistically significant less competition with
BDX when compared to DX-52-1 (p < 0.01).
These results when considered with the competition assay results for Galectin-3 imply that the
hydroxyl, carboxyl, and nitrile functional group of DX-52-1 are important to its ability to binding
to both Galectin-3 and Radixin. This might hold true for any other protein that DX-52-1 binds.
Furthermore the similarities in the BDX competition assay results suggest the possibility that the
binding site in both protein might turn to be similar. If the specific binding of DX-52-1 to Galectin3 and Radixin is due to hydrogen bonding and/or a salt bridge then that could conceivably explain
the important of the hydroxyl and carboxyl group respectively. Kahsai et al had proposed that the
mechanism for DX-52-1 bonding is the ejection of the nitrile group resulting in a carbocation that
is then attacked by a nucleophilic amino acid side chain on a protein (12). The results for the BDX
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competition assays for 1X-108 with Radixin and Galectin-3 mostly support that proposed
mechanism. However the mechanism would predict a complete loss of competition with BDX.
Perhaps there is a minor secondary mechanism that permits some competition with BDX to be
retained. The placement of bromine on the DX-52-1 phenyl ring in the para position to the methoxy
group did not seem to reduce the ability of DX-52-1 to compete with BDX in the case of BO2-7.
There was no statistically significant difference between the results of BO1-180 and BO1-95 so
the bromine had no effect in that case either. It can be concluded that the position on the phenyl
group para to the methoxy group is of minimal if any importance to the binding ability of DX-521, at least in regard to Galectin-3.
The results of the wound closure assays on MDA-MB-435 cells support the conclusions
derived from the BDX competition results all the more strongly. With the sole exception of BO27 every single derivative showed no anti-migratory effect on MDA-MB-435 cells at any of the
doses tested (Figure 4-4). BO2-7 on the other hand showed a strong anti-migratory effect as a
function of dose. In fact the dose response is similar to that of DX-52-1 on MDA-MB-435 cells
(Fenteany Group Unpublished Results). The fact that these results point in the same direction as
the results from the BDX competition as assay in terms of which functional groups are important,
strongly suggest that the anti-migratory effect of DX-52-1 is brought about by its interaction with
Galectin-3 and Radixin. Furthermore this convergence of results between wound closure and BDX
competition assays support the proposition that Galectin-3 and Radixin play critical roles in cell
motility.
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Figure 4-4: Wound Closure Assays of MDA-MB-435 over a 36 period with DX-52-1 Derivatives.
Concentrations range from 0 to 1µM. With the notable exception of BO2-7 all analogs show no
visible reduction in rate of wound closure. The results for BO2-7 mirrors unpublished Fenteany
Group results concerning the effect of DX-52-1 on MDA-MB-435 wound closure.
This converge of results is further joined by the outcome of the cell proliferation assays
performed on MDA-MB-435. Only BO2-7 showed a substantial reduction in the proliferation of
MDA-MB-435, while the other derivatives did not show a statistically significant difference from
their respective controls. (Figure 4-5). It can be surmised from the proliferation assay results that
the anti-proliferation properties of DX-52-1 upon MDA-MB-435 can be attributed to the Galectin3 and Radixin and as such those two proteins are likely to play a critical role in cell proliferation.
Kahsai et al had come to similar conclusion when they demonstrated that over-expression of
Galectin-3 counteracted the effect of DX-52-1 on cell motility (13).
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Figure 4-5: Cell Proliferation Assays of MDA-MB-435 over a 36 period with DX-52-1
Derivatives. The concentrations of each derivative range from 0 to 1µM (SD, n = 6). Only BO2-7
shows substantial reductions in cell count at any concentration. In fact BO2-7 shows a substantial
reduction in cell even at the lowest concentration tested. The results for BO2-7 mirrors unpublished
Fenteany Group results concerning the effect of DX-52-1 on MDA-MB-435 cell proliferation.

The successful treatment of cancer depends on the ability to inhibit the proliferation and
migration of tumor cells. The SAR results from the BDX competition, wound closure and
proliferation assays have shown the DX-52-1 phenyl group could be modified to some extent
without seriously impairing the binding properties of DX-52-1 or its anti-migratory and antiproliferation properties. Even if DX-52-1 itself cannot be used as such treatment it has successfully
demonstrated that Galectin-3 and Radixin are critically important in such an enterprise.
Furthermore the demonstrated importance of the hydroxyl, carboxyl, and nitrile groups could
provide some insight in how to design other possible anti-cancer drugs.
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